Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am. J. Respir. Crit. Care Med., 183, 788, 10.1164/rccm.2009-040GL

Raghu, 2006, Incidence and prevalence of idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med., 174, 810, 10.1164/rccm.200602-163OC

Raghu, 2014, Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11, Lancet Respir. Med., 2, 566, 10.1016/S2213-2600(14)70101-8

Raghu, 2015, An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline, Am. J. Respir. Crit. Care Med., 192, e3, 10.1164/rccm.201506-1063ST

Loveman, 2015, Comparing new treatments for idiopathic pulmonary fibrosis–a network meta-analysis, BMC Pulm. Med., 15, 37, 10.1186/s12890-015-0034-y

Aravena, 2015, Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis, PLoS One, 10, e0136160, 10.1371/journal.pone.0136160

Atkins, 2014, Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials, Respir. Med., 108, 376, 10.1016/j.rmed.2013.11.007

Richeldi, 2013, Clinical trials of investigational agents for IPF: a review of a Cochrane report, Respir. Res., 14, S4, 10.1186/1465-9921-14-S1-S4

Richeldi, 2012, Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis, Eur. Respir. Rev., 21, 147, 10.1183/09059180.00000912

Spagnolo, 2010, Non-steroid agents for idiopathic pulmonary fibrosis, Cochrane Database Syst. Rev., 8, 10.1002/14651858.CD003134.pub2

Canestaro, 2016, Drug therapy for treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis, Chest, 149, 756, 10.1016/j.chest.2015.11.013

Sakamoto, 2015, Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study, Respirology, 20, 445, 10.1111/resp.12477

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med., 6, e1000097, 10.1371/journal.pmed.1000097

Shariff, 2013, Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches, J. Med. Internet Res., 15, e164, 10.2196/jmir.2624

American Thoracic, 2002, Am. J. Respir. Crit. Care Med., 165, 277, 10.1164/ajrccm.165.2.ats01

Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin. Trials, 17, 1, 10.1016/0197-2456(95)00134-4

Sterne, 2000, Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature, J. Clin. Epidemiol., 53, 1119, 10.1016/S0895-4356(00)00242-0

Sterne, 2001, Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis, J. Clin. Epidemiol., 54, 1046, 10.1016/S0895-4356(01)00377-8

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Borenstein, 2009

DeCoster J. Meta-analysis notes. Retrieved April. 2004;1:2007.

Turner, 2014, Meta-methodology: conducting and reporting meta-analyses, J. Clin. Hypertens. (Greenwich), 16, 91, 10.1111/jch.12215

Cazzola, 2015, Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis, Eur. Respir. Rev., 24, 451, 10.1183/16000617.00002215

Wallace, 2012, Closing the gap between methodologists and end-users: r as a computational back-end, J. Stat. Softw., 49, 1

Viechtbauer, 2012, Conducting meta-analyses in R with the metafor package, J. Stat. Softw., 36, 1

Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Thorlund, 2011, The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis–a simulation study, PLoS One, 6, e25491, 10.1371/journal.pone.0025491

Homma, 2012, Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis, Respirology, 17, 467, 10.1111/j.1440-1843.2012.02132.x

Salanti, 2012, Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool, Res. Synth. Methods, 3, 80, 10.1002/jrsm.1037

Peat, 2002

Noble, 2016, Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur. Respir. J., 47, 243, 10.1183/13993003.00026-2015

Kirsten, 2015, Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF). Abstract Presented at ICLAF 2014, Pneumologie, 69

Aravena, 2015, Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis, PLoS One, 10, e0140288, 10.1371/journal.pone.0140288

Azuma, 2005, Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med., 171, 1040, 10.1164/rccm.200404-571OC

Raghu, 2012, Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis, N. Engl. J. Med., 366, 1968, 10.1056/NEJMoa1113354

Martinez, 2014, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, N. Engl. J. Med., 370, 2093, 10.1056/NEJMoa1401739

Noble, 2011, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, 377, 1760, 10.1016/S0140-6736(11)60405-4

Calzetta, 2015, Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy, Eur. J. Pharmacol., 761, 168, 10.1016/j.ejphar.2015.05.020

Calzetta, 2016, LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment, Eur. Respir. Rev.

Richeldi, 2011, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N. Engl. J. Med., 365, 1079, 10.1056/NEJMoa1103690

Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N. Engl. J. Med., 370, 2071, 10.1056/NEJMoa1402584

Taniguchi, 2010, Pirfenidone in idiopathic pulmonary fibrosis, Eur. Respir. J., 35, 821, 10.1183/09031936.00005209

Demedts, 2005, High-dose acetylcysteine in idiopathic pulmonary fibrosis, N. Engl. J. Med., 353, 2229, 10.1056/NEJMoa042976

King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N. Engl. J. Med., 370, 2083, 10.1056/NEJMoa1402582

Sakamoto, 2013, Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis, Intern Med., 52, 2495, 10.2169/internalmedicine.52.8498

Harari, 2015, Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study, Respir. Med., 109, 904, 10.1016/j.rmed.2015.04.010

Behr, 2016, Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Resp. Med., 4, 445, 10.1016/S2213-2600(16)30044-3

Cazzola, 2016, Interaction between corticosteroids and muscarinic antagonists in human airways, Pulm. Pharmacol. Ther., 36, 1, 10.1016/j.pupt.2015.11.004

Calzetta, 2015, Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia, Eur. J. Pharmacol., 765, 463, 10.1016/j.ejphar.2015.09.007

Cazzola, 2015, Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside, Respir. Med., 109, 1305, 10.1016/j.rmed.2015.08.005

Calzetta, 2015, Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways, Pulm. Pharmacol. Ther., 32, 15, 10.1016/j.pupt.2015.03.007

Cazzola, 2014, Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi, Eur. J. Pharmacol., 745, 135, 10.1016/j.ejphar.2014.10.025

Cazzola, 2015, Translational study searching for synergy between glycopyrronium and indacaterol, COPD, 12, 175, 10.3109/15412555.2014.922172

Calzetta, 2013, Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone, J. Pharmacol. Exp. Ther., 346, 414, 10.1124/jpet.113.204644

Rogliani, 2013, The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle, Pulm. Pharmacol. Ther., 26, 325, 10.1016/j.pupt.2013.01.002

Ogura, 2015, Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis, Eur. Respir. J., 45, 1382, 10.1183/09031936.00198013

European Medicines Agency. EMA/CHMP/115147/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002154/WC500103073.pdf. 2010.

Higgins, 2011

Sutton, 2002, Meta-analysis of rare and adverse event data, Expert Rev. Pharmacoecon Outcomes Res., 2, 367, 10.1586/14737167.2.4.367

Schechtman, 2002, Odds ratio, relative risk, absolute risk reduction, and the number needed to treat–which of these should we use?, Value Health, 5, 431, 10.1046/J.1524-4733.2002.55150.x

Raghu, 2012, Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials, Am. J. Respir. Crit. Care Med., 185, 1044, 10.1164/rccm.201201-0006PP

Antoniou, 2013, Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future, Eur. Respir. Rev., 22, 281, 10.1183/09059180.00002113

Rogliani, 2008, HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema, Respir. Med., 102, 1753, 10.1016/j.rmed.2008.07.010

Wuyts, 2014, Combination therapy: the future of management for idiopathic pulmonary fibrosis?, lancet Respir. Med., 2, 933, 10.1016/S2213-2600(14)70232-2

Vancheri, 2013, A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer, Eur. Respir. J., 41, 262, 10.1183/09031936.00115112

Rogliani, 2008, New perspectives in the treatment of idiopathic pulmonary fibrosis, Ther. Adv. Respir. Dis., 2, 75, 10.1177/1753465808089363